The Global Plaque Modification Devices Market Size is projected to grow at a CAGR of 7.16% during the forecast period from 2026 to 2034 | DelveInsight

The Plaque Modification Devices market is estimated at USD 3,622.27 million in 2025 and is projected to reach USD 6,725.92 million by 2034. Growth is anchored in the rising prevalence of atherosclerosis and calcified CAD/PAD, the shift toward minimally invasive endovascular procedures, and continuous product innovation.

DelveInsight's Plaque Modification Devices Market Insights Report 2034 provides the current and forecast market analysis, individual leading Plaque Modification Devices companies' market shares, challenges, Plaque Modification Devices Market Drivers, barriers, trends, and key market Plaque Modification Devices companies in the market.

To read more about the latest highlights related to the Plaque Modification Devices Market:
https://www.delveinsight.com/sample-request/plaque-modification-devices-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Key Takeaways from the Plaque Modification Devices Market Report

* In October 2025, Elixir Medical announced the full market release of its LithiXTM Hertz Contact (HC) Intravascular Lithotripsy System (IVL), following CE Mark approval. Strategic significance: Expands access to advanced IVL technology for treating calcified cardiovascular disease across Europe.
* In January 2025, Boston Scientific Corporation entered into a definitive agreement to acquire Bolt Medical, Inc., developer of a laser-based intravascular lithotripsy platform. Strategic significance: Strengthens Boston Scientific's IVL portfolio for coronary and peripheral artery disease treatment.
* In March 2025, Abbott received U.S. FDA approval for an investigational device exemption (IDE) for its Coronary Intravascular Lithotripsy (IVL) System, enabling the TECTONIC Coronary Artery Disease IVL clinical trial across 47 U.S. sites. Strategic significance: Advances clinical evidence supporting IVL treatment of severe coronary calcification.
* The global Plaque Modification Devices market is growing at a CAGR of 7.16% during the forecast period from 2026 to 2034.
* The principal drivers are the rising prevalence of atherosclerosis and calcified coronary/peripheral artery disease; increasing adoption of minimally invasive endovascular procedures; and rising product development activity among key market players, including innovations in intravascular lithotripsy, super high-pressure balloons, and next-generation atherectomy systems.
* The leading Plaque Modification Devices Companies include Abbott, Boston Scientific Corporation, Medtronic, Johnson & Johnson Services Inc., BD, Terumo Corporation, Koninklijke Philips N.V., Nipro Corporation, AngioDynamics, Inc., Elixir Medical, Avinger Inc., SIS Medical, BrosMed Medical Co., Ltd., OrbusNeich, MicroPort Scientific Corporation, Cagent Vascular, INVAMED, Cordis, Sonosemi Medical Co., Ltd., and APR Medtech Ltd., among others.

To know more about why North America is leading the market growth in the Plaque Modification Devices Market, Get a snapshot:
https://www.delveinsight.com/sample-request/plaque-modification-devices-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Plaque Modification Devices Overview

Plaque modification devices are specialized cardiovascular tools used to treat hardened, calcified, and complex atherosclerotic plaques in the coronary and peripheral arteries when standard balloon angioplasty cannot adequately open the vessel. These devices, including atherectomy systems, intravascular lithotripsy (IVL), cutting balloons, scoring balloons, and ultra high-pressure balloons, are designed to break, shave, score, or fracture calcified plaque to improve vessel compliance.

Plaque Modification Devices Market Key Growth Drivers

* According to the National Health Institute (2024), atherosclerosis is a chronic inflammatory disease of the arteries and is the underlying cause of about 50% of all deaths in westernized society, driving demand for devices that can effectively treat hardened, calcified lesions.
* The British Heart Foundation (2025) estimates global prevalence of coronary (ischaemic) heart disease at 250 million and peripheral arterial (vascular) disease at 110 million, while the Institute for Health Metrics and Evaluation (2023) reports 113 million people aged 40 and older globally living with peripheral artery disease.
* The rising prevalence of CAD and PAD, driven by risk factors such as aging populations, diabetes, obesity, hypertension, and sedentary lifestyles, has significantly increased the need for effective interventional treatments and better lesion preparation.
* The shift toward minimally invasive endovascular procedures is driving demand for advanced devices that ensure safer and more efficient treatment of complex, calcified lesions, as healthcare systems increasingly favor catheter-based interventions over open surgery.
* Increasing product development activity among key manufacturers is expanding clinical applicability, exemplified by FastWave Medical's October 2025 first-in-human and pre-clinical data for its Sola coronary laser intravascular lithotripsy (L-IVL) system.
* Continuous innovation and strategic consolidation, including Boston Scientific's January 2025 agreement to acquire Bolt Medical, Inc., are expanding the therapeutic toolkit for plaque modification and improving physician confidence in complex PCI.

Get a sneak peek at the Plaque Modification Devices Market Dynamics:
https://www.delveinsight.com/sample-request/plaque-modification-devices-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Plaque Modification Devices Market Segment Analysis

The Plaque Modification Devices Market by Product Type (Atherectomy Devices, Intravascular Lithotripsy (IVL) Systems, Specialized Balloons [Cutting Balloons, Scoring Balloons, and Others]), Application (Coronary Artery Disease and Peripheral Artery Disease), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

By Product Type:

The "Others" sub-segment of the Specialized Balloons category, which includes super high-pressure balloons (SHPBs), non-compliant (NC) balloons, and semi-compliant (SC) balloons, is expected to hold the largest revenue share of 46.52% in 2025. SHPBs are designed to withstand extremely high inflation pressures, often up to 35-40 atmospheres, enabling safe dilation of rigid, fibrotic, or heavily calcified plaques that are difficult to treat with conventional balloons, while NC and SC balloons enhance deliverability and reduce procedural complications across a broader range of lesions.

By Application:

Coronary Artery Disease dominates the market with a 61.71% revenue share in 2025, reflecting both the largest global disease burden and the most significant source of complex coronary lesions requiring specialized intervention. A 2024 JACC study estimated 315 million prevalent cases of CAD worldwide, driving greater need for scoring balloons, cutting balloons, rotational and orbital atherectomy devices, and IVL to restore vessel compliance for successful stent placement.

By Geography:

North America is expected to account for the highest share at 38.87% in 2025, driven by advanced healthcare infrastructure, high adoption of technologically advanced devices, and increasing prevalence of PAD and CAD. Asia-Pacific is the fastest-growing region, projected to grow at a CAGR of 8.77% during the forecast period, fueled by rising CAD and PAD prevalence and a high burden of metabolic risk factors, particularly in China.

Which MedTech key players in the Plaque Modification Devices Market are set to emerge as the trendsetter, explore:
https://www.delveinsight.com/sample-request/plaque-modification-devices-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Plaque Modification Devices Market Competitive Landscape

The Plaque Modification Devices market is moderately concentrated yet dynamic, shaped by a mix of established medical device giants and specialized innovators. Leading players hold significant market share due to extensive product portfolios, strong global distribution channels, and ongoing R&D investments to enhance device performance and clinical outcomes, while a growing number of niche and emerging companies are introducing novel technologies such as advanced atherectomy systems, intravascular lithotripsy, and specialty balloon catheters. Strategic activities including mergers and acquisitions, partnerships, and regulatory approvals continue to shape market positioning across the sector.

Plaque Modification Devices Companies

Abbott, Boston Scientific Corporation, Medtronic, Johnson & Johnson Services Inc., BD, Terumo Corporation, Koninklijke Philips N.V., Nipro Corporation, AngioDynamics, Inc., Elixir Medical, Avinger Inc., SIS Medical, BrosMed Medical Co., Ltd., OrbusNeich, MicroPort Scientific Corporation, Cagent Vascular, INVAMED, Cordis, Sonosemi Medical Co., Ltd., APR Medtech Ltd., and others.

Plaque Modification Devices Market Restraints

Despite strong momentum, the Plaque Modification Devices market faces material constraints. The inherent risk of procedural complications makes many clinicians cautious about routine use, especially in complex or fragile vascular anatomies. Additionally, the market is significantly limited by rigorous regulatory clearance standards imposed by agencies such as the U.S. FDA, the European Medicines Agency (EMA), and regulatory bodies across Asia-Pacific, which make it challenging for manufacturers to bring new technologies to market quickly.

Interested in knowing the Plaque Modification Devices Market by 2034? Click to get a snapshot of the Plaque Modification Devices Market Trends:
https://www.delveinsight.com/sample-request/plaque-modification-devices-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Scope of the Plaque Modification Devices Market Report

* Coverage- Global
* Study Period- 2023 to 2034
* Forecast Period- 2026-2034
* Plaque Modification Devices Companies- Abbott, Boston Scientific Corporation, Medtronic, Johnson & Johnson Services Inc., BD, Terumo Corporation, Koninklijke Philips N.V., Nipro Corporation, AngioDynamics, Inc., Elixir Medical, Avinger Inc., SIS Medical, BrosMed Medical Co., Ltd., OrbusNeich, MicroPort Scientific Corporation, Cagent Vascular, INVAMED, Cordis, Sonosemi Medical Co., Ltd., APR Medtech Ltd., and others.
* Plaque Modification Devices Market Restraints and Regulatory Analysis
* Plaque Modification Devices Porter Five Forces Analysis and Market Assessment

Explore more information of the Plaque Modification Devices Market Insights:
https://www.delveinsight.com/sample-request/plaque-modification-devices-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Table of Contents

1. Plaque Modification Devices Market Report Introduction
2. Plaque Modification Devices Market Executive Summary
3. Plaque Modification Devices Market Key Factors Analysis
4. Impact Analysis
5. Regulatory Analysis
6. Plaque Modification Devices Market Porter's Five Forces Analysis
7. Plaque Modification Devices Market Assessment
8. Competitive Landscape
9. Startup Funding & Investment Trends
10. Plaque Modification Devices Market Company and Product Profiles
11. KOL Views
12. Project Approach
13. About DelveInsight
14. Disclaimer & Contact Us

Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.